Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more
Ionis Pharmaceuticals Inc (IONS) - Total Assets
Latest total assets as of September 2025: $3.03 Billion USD
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) holds total assets worth $3.03 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ionis Pharmaceuticals Inc - Total Assets Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ionis Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ionis Pharmaceuticals Inc's total assets of $3.03 Billion consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $92.19 Million | 3.1% |
| Inventory | $12.51 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ionis Pharmaceuticals Inc's current assets represent 87.2% of total assets in 2024, an increase from 44.2% in 1990.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, down from 41.9% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.
Ionis Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Ionis Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ionis Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ionis Pharmaceuticals Inc generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ionis Pharmaceuticals Inc is currently not profitable relative to its asset base.
Ionis Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.79 | 8.91 | 7.34 |
| Quick Ratio | 2.78 | 8.82 | 7.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.62 Billion | $ 2.41 Billion | $ 1.84 Billion |
Ionis Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Ionis Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.09 |
| Latest Market Cap to Assets Ratio | 3.87 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | $3.00 Billion |
| Market Capitalization | $11.61 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ionis Pharmaceuticals Inc's assets at a significant premium ( 3.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Ionis Pharmaceuticals Inc's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ionis Pharmaceuticals Inc (1990–2024)
The table below shows the annual total assets of Ionis Pharmaceuticals Inc from 1990 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.00 Billion | +0.45% |
| 2023-12-31 | $2.99 Billion | +18.00% |
| 2022-12-31 | $2.53 Billion | -2.99% |
| 2021-12-31 | $2.61 Billion | +9.29% |
| 2020-12-31 | $2.39 Billion | -26.07% |
| 2019-12-31 | $3.23 Billion | +21.19% |
| 2018-12-31 | $2.67 Billion | +101.80% |
| 2017-12-31 | $1.32 Billion | +44.88% |
| 2016-12-31 | $912.47 Million | -4.56% |
| 2015-12-31 | $956.11 Million | +0.03% |
| 2014-12-31 | $955.81 Million | +12.83% |
| 2013-12-31 | $847.16 Million | +55.25% |
| 2012-12-31 | $545.69 Million | +12.54% |
| 2011-12-31 | $484.89 Million | -11.91% |
| 2010-12-31 | $550.48 Million | -16.24% |
| 2009-12-31 | $657.18 Million | +14.46% |
| 2008-12-31 | $574.15 Million | +121.80% |
| 2007-12-31 | $258.86 Million | +1.15% |
| 2006-12-31 | $255.91 Million | +53.82% |
| 2005-12-31 | $166.37 Million | -20.18% |
| 2004-12-31 | $208.43 Million | -37.77% |
| 2003-12-31 | $334.94 Million | -23.65% |
| 2002-12-31 | $438.68 Million | +5.18% |
| 2001-12-31 | $417.06 Million | +127.58% |
| 2000-12-31 | $183.26 Million | +77.73% |
| 1999-12-31 | $103.11 Million | +7.29% |
| 1998-12-31 | $96.10 Million | -18.49% |
| 1997-12-31 | $117.90 Million | +16.39% |
| 1996-12-31 | $101.30 Million | +1.71% |
| 1995-12-31 | $99.60 Million | +49.55% |
| 1994-12-31 | $66.60 Million | -15.48% |
| 1993-12-31 | $78.80 Million | +41.98% |
| 1992-12-31 | $55.50 Million | -24.59% |
| 1991-12-31 | $73.60 Million | +1611.63% |
| 1990-12-31 | $4.30 Million | -- |